Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin‐Converting Enzyme Inhibitor or Angiotensin‐Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure

BACKGROUND: Outcomes data among patients with heart failure (HF) with reduced ejection fraction treated with sacubitril/valsartan (SAC/VAL) are largely limited to clinical trial results. We compared hospitalization and healthcare costs among real‐world patients with HF with reduced ejection fraction...

Descripción completa

Detalles Bibliográficos
Autores principales: Albert, Nancy M., Swindle, Jason P., Buysman, Erin K., Chang, Chunlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512093/
https://www.ncbi.nlm.nih.gov/pubmed/31023122
http://dx.doi.org/10.1161/JAHA.118.011089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512093/
https://www.ncbi.nlm.nih.gov/pubmed/31023122
http://dx.doi.org/10.1161/JAHA.118.011089

Ejemplares similares